Aladdin J Mohammad1, Rona M Smith2, Yok W Chow2, Afzal N Chaudhry2, David R W Jayne2. 1. From the Department of Renal Medicine, Addenbrooke's Hospital, Cambridge, UK; Department of Clinical Sciences, Rheumatology, Lund University, Lund, Sweden; Department of Medicine, Hospital Pantai Ayer Keroh, Melaka, Malaysia.A.J. Mohammad, MD, PhD, Department of Renal Medicine, Addenbrooke's Hospital, and Department of Clinical Sciences, Rheumatology, Lund University; R.M. Smith, MA, MB BChir, MRCP, Department of Renal Medicine, Addenbrooke's Hospital; Y.W. Chow, MD(USM), MRCP( UK), MRCPE, FRCP(Edinburgh), AM(MAL), Department of Medicine, Hospital Pantai Ayer Keroh Melaka; A.N. Chaudhry, MBBS, PhD, FRCP, FHEA, FACad MEd, Department of Renal Medicine, Addenbrooke's Hospital; D.R. Jayne, MD, FRCP, Department of Renal Medicine, Addenbrooke's Hospital. aladdin.mohammad@med.lu.se. 2. From the Department of Renal Medicine, Addenbrooke's Hospital, Cambridge, UK; Department of Clinical Sciences, Rheumatology, Lund University, Lund, Sweden; Department of Medicine, Hospital Pantai Ayer Keroh, Melaka, Malaysia.A.J. Mohammad, MD, PhD, Department of Renal Medicine, Addenbrooke's Hospital, and Department of Clinical Sciences, Rheumatology, Lund University; R.M. Smith, MA, MB BChir, MRCP, Department of Renal Medicine, Addenbrooke's Hospital; Y.W. Chow, MD(USM), MRCP( UK), MRCPE, FRCP(Edinburgh), AM(MAL), Department of Medicine, Hospital Pantai Ayer Keroh Melaka; A.N. Chaudhry, MBBS, PhD, FRCP, FHEA, FACad MEd, Department of Renal Medicine, Addenbrooke's Hospital; D.R. Jayne, MD, FRCP, Department of Renal Medicine, Addenbrooke's Hospital.
Abstract
OBJECTIVE: To study the efficacy and safety of anti-CD52 antibody (alemtuzumab) in the treatment of refractory and relapsing Behçet disease (BD). METHODS: Thirty-two patients (22 women) with BD received 60 courses of alemtuzumab between 1994 and 2013. Three-dose regimens were used: 134 mg in 21 courses (Group 1), 95 mg in 18 courses (Group 2), and 60 mg in 21 courses (Group 3). Immunosuppressive drugs were stopped at the time of alemtuzumab, and prednisolone was reduced according to clinical response. Treatment response was assessed by clinical status, inflammatory activity, prednisolone dose, and the need for subsequent immunosuppressive drugs and disease relapse. RESULTS: After the first alemtuzumab course, 27 of 32 patients (84%) achieved partial or complete remission (CR). Fifty of 60 courses (83%) resulted in remission (66% CR) without differences in remission rates between dosing regimens. Profound lymphocyte depletion occurred after all courses. Relapse-free survival rates were 83.6% at 6 months and 52.8% at 12 months, and were higher among Group 1 patients (Group 1: 100% and 77.8%, Group 2: 81.3% and 37.5%, and Group 3: 65.0% and 37.1%, p < 0.001). Mild to moderate infusion reactions occurred after 16 courses (27%). Eight patients (25%) developed symptomatic thyroid disease. CONCLUSION: Alemtuzumab led to remission in the majority of patients with difficult-to-treat BD. Relapse was common and may be associated with lower dosing. Adverse events included infusion reactions and new autoimmunity. Achieving complete lymphocyte depletion did not affect the remission rate or duration.
OBJECTIVE: To study the efficacy and safety of anti-CD52 antibody (alemtuzumab) in the treatment of refractory and relapsing Behçet disease (BD). METHODS: Thirty-two patients (22 women) with BD received 60 courses of alemtuzumab between 1994 and 2013. Three-dose regimens were used: 134 mg in 21 courses (Group 1), 95 mg in 18 courses (Group 2), and 60 mg in 21 courses (Group 3). Immunosuppressive drugs were stopped at the time of alemtuzumab, and prednisolone was reduced according to clinical response. Treatment response was assessed by clinical status, inflammatory activity, prednisolone dose, and the need for subsequent immunosuppressive drugs and disease relapse. RESULTS: After the first alemtuzumab course, 27 of 32 patients (84%) achieved partial or complete remission (CR). Fifty of 60 courses (83%) resulted in remission (66% CR) without differences in remission rates between dosing regimens. Profound lymphocyte depletion occurred after all courses. Relapse-free survival rates were 83.6% at 6 months and 52.8% at 12 months, and were higher among Group 1 patients (Group 1: 100% and 77.8%, Group 2: 81.3% and 37.5%, and Group 3: 65.0% and 37.1%, p < 0.001). Mild to moderate infusion reactions occurred after 16 courses (27%). Eight patients (25%) developed symptomatic thyroid disease. CONCLUSION:Alemtuzumab led to remission in the majority of patients with difficult-to-treat BD. Relapse was common and may be associated with lower dosing. Adverse events included infusion reactions and new autoimmunity. Achieving complete lymphocyte depletion did not affect the remission rate or duration.
Authors: Faye A H Cooles; Amy E Anderson; Tracey Drayton; Rachel A Harry; Julie Diboll; Lee Munro; Nishanthi Thalayasingham; Andrew J K Östör; John D Isaacs Journal: Arthritis Res Ther Date: 2016-12-20 Impact factor: 5.156